Citations

Clear

2 citation(s) found for "Severson, Paul".

A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors
Garmezy, Benjamin , Borad, Mitesh J. , Bahleda, Rastilav , Perez, Cesar A. , Chen, Li‐Tzong , Kato, Shumei , Oh, Do‐Youn , Severson, Paul , Tam, Betty Y. , Quah, Cheng S. , Harding, James J , Borad, Mitesh J , Chen, Li-Tzong , Garmezy, Benjamin , Harding, James J.

Mayo Clinic

Cancer Research Communications | April 11, 2024 | Volume: 4 | Issue: 4 | Pages: 1165-1173

10.1158/2767-9764.crc-24-0137 | PMID 38602417 Get It

Abstract Purpose: Despite efficacy of approved FGFR inhibitors, emergence of polyclonal secondary mutations in the FGFR kinase domain leads to acquired resistance. KIN-3248 is a selective, irreversible, orally bioavailable, small-molecule inhibitor of FGFR1-4 that blocks both primary oncogenic and secondary kinase domain resistance FGFR alterations. Experimental Design: A first-in-human, phase I study of KIN-3248 was conducted in patients with advanced solid tumors harboring FGFR2 and/or FGFR3 gene alterations (NCT05242822). The primary objective was determination of MTD/recommended phase II dose (RP2D). Secondary and exploratory objectives included antitumor activity, pharmacokinetics, pharmacodynamics, and molecular response by circulating tumor DNA (ctDNA) clearance. Results: Fifty-four patients received doses ranging from 5 to 50 mg orally daily across six cohorts. Intrahepatic cholangiocarcinoma (48.1%), gastric (9.3%), and urothelial (7.4%) were the most common tumors. Tumors harbored FGFR2 (68.5%) or FGFR3 (31.5%) alterations—23 (42.6%) received prior FGFR inhibitors. One dose-limiting toxicity (hypersensitivity) occurred in cohort 1 (5 mg). Treatment-related, adverse events included hyperphosphatemia, diarrhea, and stomatitis. The MTD/RP2D was not established. Exposure was dose proportional and concordant with hyperphosphatemia. Five partial responses were observed; 4 in FGFR inhibitor naïve and 1 in FGFR pretreated patients. Pretreatment ctDNA profiling confirmed FGFR2/3 alterations in 63.3% of cases and clearance at cycle 2 associated with radiographic response. Conclusion: The trial was terminated early for commercial considerations; therefore, RP2D was not established. Preliminary clinical data suggest that KIN-3248 is a safe, oral FGFR1-4 inhibitor with favorable pharmacokinetic parameters, though further dose escalation was required to nominate the MTD/RP2D. Significance: KIN-3248 was a rationally designed, next generation selective FGFR inhibitor, that was effective in interfering with both FGFR wild-type and mutant signaling. Clinical data indicate that KIN-3248 is safe with a signal of antitumor activity. Translational science support the mechanism of action in that serum phosphate was proportional with exposure, paired biopsies suggested phospho-ERK inhibition (a downstream target of FGFR2/3), and ctDNA clearance may act as a RECIST response surrogate.
S1036 High-Definition Probe-Based Confocal Laser Endomicroscopy for the Detection of Neoplasia in Patients With Barrett's Esophagus: A Systematic Review and Meta-Analysis
Chahine, Anastasia , DeMeester, Steven R. , Wang, Kenneth T. , Ayub, Kamran, Buckley, P., Leggett, Philip, Severson, Paul , Samarasena, Jason , Buckley, Paul

Mayo Clinic

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S491-S491

10.14309/01.ajg.0000777676.92475.42 Get It